Altretamine hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 573708

CAS#: 2975-00-0 (HCl)

Description: Altretamine hydrochloride is an alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.


Chemical Structure

img
Altretamine hydrochloride
CAS# 2975-00-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 573708
Name: Altretamine hydrochloride
CAS#: 2975-00-0 (HCl)
Chemical Formula: C9H19ClN6
Exact Mass: 246.136
Molecular Weight: 246.74
Elemental Analysis: C, 43.81; H, 7.76; Cl, 14.37; N, 34.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2975-00-0 (HCl)   645-05-6 (free base)    

Synonym: Altretamine hydrochloride, Altretamine HCl, Hexamethylmelamine HCl

IUPAC/Chemical Name: 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl-, monohydrochloride

InChi Key: AKAQBNIEQUSIJL-UHFFFAOYSA-N

InChi Code: 1S/C9H18N6.ClH/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6;/h1-6H3;1H

SMILES Code: n1c(nc(nc1N(C)C)N(C)C)N(C)C.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 246.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi: 10.1007/s00280-008-0703-0. Epub 2008 Feb 28. PubMed PMID: 18305940.

2: Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):224-8. PubMed PMID: 15086720.

3: Chan JK, Loizzi V, Manetta A, Berman ML. Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):368-71. PubMed PMID: 14751188.

4: Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol. 2003 Feb;88(2):118-22. PubMed PMID: 12586589.

5: Olver I, Davy M, Lüftner D, Park SH, Egorin M, Ellis A, Webster L. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. Cancer Chemother Pharmacol. 2001 Aug;48(2):109-14. PubMed PMID: 11561776.

6: Zon RT, McClean J, Helman D, Ansari R, Picus J, Sandler A, Williams SD, Loehrer PJ Sr. Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial. Invest New Drugs. 2001;19(3):229-31. PubMed PMID: 11561679.

7: Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol. 2001 Aug;82(2):317-22. PubMed PMID: 11531286.

8: Malik IA. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol. 2001 Feb;31(2):69-73. PubMed PMID: 11302345.

9: Gershanovich ML, Livshits ME, Antipenkova VI. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma]. Vopr Onkol. 2000;46(5):604-7. Russian. PubMed PMID: 11202196.

10: Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998 Jun;69(3):226-9. PubMed PMID: 9648592.